home / stock / pypd / pypd news

PYPD News and Press, PolyPid Ltd.

Stock Information
Company Name: PolyPid Ltd.
Stock Symbol: PYPD
Market: NASDAQ
Website: polypid.com
Menu
PYPD PYPD Quote PYPD Short PYPD News PYPD Articles PYPD Message Board
Get PYPD Alerts

News, Short Squeeze, Breakout and More Instantly...
PYPD - PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial

After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned...
PYPD - PolyPid GAAP EPS of $0.28 beats by $0.56

2023-05-10 07:25:24 ET PolyPid press release ( NASDAQ: PYPD ): Q1 GAAP EPS of $0.28 beats by $0.56 . As of March 31, 2023, the Company had cash and cash equivalents and deposits in the amount of $13.4 million, Research and development (R&D) expenses f...

PYPD - PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Prod...

PYPD - PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results...
PYPD - PolyPid receive non-compliance letter from Nasdaq

2023-04-14 16:27:35 ET PolyPid ( NASDAQ: PYPD ) said it had received a letter from the listing firm Nasdaq stating it was no longer in compliance with the minimum equity requirement for continued listing The Company has 45 days, or until May 25, to submit a plan to regain comp...

PYPD - PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PETACH TIKVA, Israel, April 14, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a letter from the Listing Qualifications sta...

PYPD - PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

Company Also Restructures Existing Kreos Loan, Deferring Over $3 Million of Repayment PETACH TIKVA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve...
PYPD - PolyPid stock slides on pricing securities offering

2023-03-29 08:31:40 ET PolyPid ( NASDAQ: PYPD ) shares fell 18% premarket on Wednesday after the biopharma company priced its securities offering to raise around $6.2M in gross proceeds. The offering comprises 14.66M ordinary shares, issued at $0.42 each. The under...

PYPD - PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the pricing of an underwritten public offering of 14,660,000...

PYPD - PolyPid proposes stock offering, shares fall after hours

2023-03-28 16:25:18 ET PolyPid ( NASDAQ: PYPD ) said Tuesday it commenced an underwritten public offering of its ordinary shares. In addition, PolyPid intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares. ...
Next 10